[go: up one dir, main page]

PE20142189A1 - ANTIBODIES TARGETED AGAINST MATRIX METALOPROTEINASES 9 - Google Patents

ANTIBODIES TARGETED AGAINST MATRIX METALOPROTEINASES 9

Info

Publication number
PE20142189A1
PE20142189A1 PE2014001335A PE2014001335A PE20142189A1 PE 20142189 A1 PE20142189 A1 PE 20142189A1 PE 2014001335 A PE2014001335 A PE 2014001335A PE 2014001335 A PE2014001335 A PE 2014001335A PE 20142189 A1 PE20142189 A1 PE 20142189A1
Authority
PE
Peru
Prior art keywords
targeted against
antibodies targeted
against matrix
mmp9
seq
Prior art date
Application number
PE2014001335A
Other languages
Spanish (es)
Inventor
Joanne I Adamkewicz
Victoria Smith
Zung Thai
Michael J Hawkins
Original Assignee
Gilead Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52388256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142189(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Biologics Inc filed Critical Gilead Biologics Inc
Publication of PE20142189A1 publication Critical patent/PE20142189A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: UN ANTICUERPO AISLADO O FRAGMENTO DEL MISMO QUE SE UNE A METALOPROTEINASA DE MATRIZ 9 (MMP9) QUE COMPRENDE UNA REGIEN VARIABLE DE LA CADENA PESADA (VH) QUE TIENE UNA REGION DETERMINANTE DE COMPLEMENTARIDAD (CDR) CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 15; Y EN DONDE LA REGION VL COMPRENDE LA SECUENCIA DE AMINOACIDOS QUE SE INDICA EN SEQ ID NOs: 16 Y 17. DICHA COMPOSICION ES UN INHIBIDOR DE MMP9. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ES UTIL EN EL TRATAMIENTO DE CANCER Y ENFERMEDADES AUTOINMUNES.REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: AN ISOLATED ANTIBODY OR FRAGMENT OF ITSELF THAT IS BINDING TO MATRIX METALOPROTEINASE 9 (MMP9) THAT INCLUDES A VARIABLE REGION OF THE HEAVY CHAIN (VH) THAT HAS A DETERMARED COMPLETE REGION OF CDR A SEQUENCE OF AMINO ACIDS OF SEQ ID NO: 15; AND WHERE THE VL REGION INCLUDES THE SEQUENCE OF AMINO ACIDS INDICATED IN SEQ ID NOs: 16 AND 17. SAID COMPOSITION IS AN INHIBITOR OF MMP9. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION THAT IS USEFUL IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES.

PE2014001335A 2012-02-29 2013-02-28 ANTIBODIES TARGETED AGAINST MATRIX METALOPROTEINASES 9 PE20142189A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201213201202A 2012-02-29 2012-02-29
US201261605181P 2012-02-29 2012-02-29
US201361755444P 2013-01-22 2013-01-22

Publications (1)

Publication Number Publication Date
PE20142189A1 true PE20142189A1 (en) 2014-12-29

Family

ID=52388256

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001335A PE20142189A1 (en) 2012-02-29 2013-02-28 ANTIBODIES TARGETED AGAINST MATRIX METALOPROTEINASES 9

Country Status (1)

Country Link
PE (1) PE20142189A1 (en)

Similar Documents

Publication Publication Date Title
PE20150023A1 (en) ST2 ANTIGEN BINDING PROTEINS
DOP2017000031A (en) ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN BINDING FRAGMENT, A PHARMACEUTICAL COMPOSITION AND USE
MX2018007630A (en) Antibodies to matrix metalloproteinase 9.
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
PE20140190A1 (en) NOTUM PROTEIN MODULATORS AND METHODS OF USE
PE20160528A1 (en) ANTIBODIES
MX380358B (en) IGF-1R antibody and its use as a target-specific vehicle for cancer treatment.
PE20150002A1 (en) ANTI-FCRN ANTIBODIES
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
PE20161032A1 (en) HUMANIZED ANTI-TAU ANTIBODIES (PS422) AND METHODS OF USE
PE20170665A1 (en) HUMANIZED ANTI-TAU ANTIBODIES
ES2670621T3 (en) Antibodies that bind to OX40 and its uses
PE20171103A1 (en) HETERODIMERIC ANTIBODIES THAT BIND TO CD3 AND CD38
ECSP14001260A (en) BI-SPECIFIC IMMUNOLIGANTS TARGETED AGAINST TNF AND IL-17 CROSS REFERENCE TO RELATED REQUESTS
ECSP14001249A (en) IMMUNOBINDERS TARGETED AGAINST TNF
PE20121563A1 (en) ANTIBODIES THAT SPECIFICALLY BIND THE EPHA2 RECEIVER
MX377716B (en) APLNR MODULATORS AND THEIR USES.
IN2015DN02349A (en)
AU2016335217A8 (en) Antigen receptors and uses thereof
PE20141683A1 (en) SPECIFIC MONOCLONAL ANTIBODIES FOR RESPIRATORY SYNCITIAL VIRUS (RSV) M2-1 ANTIGEN
PE20191743A1 (en) BI-SPECIFIC ANTIBODIES ANTI-PD-L1-ANTI-TIM3
MX2015009819A (en) SPECIFIC HUMAN ANTIBODY TO HUMAN METAPNEUMOVIRUS, OR FRAGMENT OF UNION TO THE ANTIGEN OF THE SAME.
MX2016011177A (en) Antibodies to matrix metalloproteinase 9 and methods of use thereof.
AR120914A1 (en) TGF-b-RII BINDING PROTEINS
AR082160A1 (en) MONOCLONAL ANTIBODIES DIRECTED AGAINST TETANIC TOXIN

Legal Events

Date Code Title Description
FD Application declared void or lapsed